# Combination of Inhaled DNase, Baricitinib and Tocilizumab in Severe COVID-19

> **NCT05279391** · NA · UNKNOWN · sponsor: **Democritus University of Thrace** · enrollment: 150 (estimated)

## Conditions studied

- COVID-19 Severe Respiratory Failure

## Interventions

- **DRUG:** Dexamethasone
- **DRUG:** Low molecular weight heparin
- **DRUG:** Anakinra 100Mg/0.67Ml Inj Syringe
- **DRUG:** Tocilizumab
- **DRUG:** Baricitinib
- **DRUG:** Dornase Alfa Inhalant Product

## Key facts

- **NCT ID:** NCT05279391
- **Lead sponsor:** Democritus University of Thrace
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-10-25
- **Primary completion:** 2021-11-30
- **Final completion:** 2023-12-31
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2022-03-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05279391

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05279391, "Combination of Inhaled DNase, Baricitinib and Tocilizumab in Severe COVID-19". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT05279391. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*